Last reviewed · How we verify
Anti-Retroviral Agents
Inhibits HIV reverse transcriptase
Inhibits HIV reverse transcriptase Used for HIV infection.
At a glance
| Generic name | Anti-Retroviral Agents |
|---|---|
| Sponsor | Shanghai Public Health Clinical Center |
| Drug class | Nucleoside Reverse Transcriptase Inhibitor |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
Anti-Retroviral Agents, such as those in the class of Nucleoside Reverse Transcriptase Inhibitors (NRTIs), work by inhibiting the reverse transcriptase enzyme, which is essential for the replication of retroviruses like HIV.
Approved indications
- HIV infection
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
- Opioid, HIV and Immune System (PHASE4)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)
- Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption (PHASE2)
- Evaluation of Multiple Interventions to Improve HIV Treatment Outcomes Among People Who Inject Drugs in India (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |